GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » We Can Medicines Co Ltd (ROCO:6929) » Definitions » Return-on-Tangible-Asset

We Can Medicines Co (ROCO:6929) Return-on-Tangible-Asset : -1.62% (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is We Can Medicines Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. We Can Medicines Co's annualized Net Income for the quarter that ended in Mar. 2025 was NT$-50 Mil. We Can Medicines Co's average total tangible assets for the quarter that ended in Mar. 2025 was NT$3,063 Mil. Therefore, We Can Medicines Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -1.62%.

The historical rank and industry rank for We Can Medicines Co's Return-on-Tangible-Asset or its related term are showing as below:

ROCO:6929' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.24   Med: 1.96   Max: 4.19
Current: -2.24

During the past 5 years, We Can Medicines Co's highest Return-on-Tangible-Asset was 4.19%. The lowest was -2.24%. And the median was 1.96%.

ROCO:6929's Return-on-Tangible-Asset is ranked worse than
79.63% of 1934 companies
in the Consumer Packaged Goods industry
Industry Median: 3.62 vs ROCO:6929: -2.24

We Can Medicines Co Return-on-Tangible-Asset Historical Data

The historical data trend for We Can Medicines Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

We Can Medicines Co Return-on-Tangible-Asset Chart

We Can Medicines Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
2.43 1.96 4.19 0.55 -1.59

We Can Medicines Co Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 -0.41 -2.65 -4.35 -1.62

Competitive Comparison of We Can Medicines Co's Return-on-Tangible-Asset

For the Packaged Foods subindustry, We Can Medicines Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


We Can Medicines Co's Return-on-Tangible-Asset Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where We Can Medicines Co's Return-on-Tangible-Asset falls into.


;
;

We Can Medicines Co Return-on-Tangible-Asset Calculation

We Can Medicines Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-47.176/( (2856.985+3078.647)/ 2 )
=-47.176/2967.816
=-1.59 %

We Can Medicines Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-49.7/( (3078.647+3046.947)/ 2 )
=-49.7/3062.797
=-1.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


We Can Medicines Co  (ROCO:6929) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


We Can Medicines Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of We Can Medicines Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


We Can Medicines Co Business Description

Traded in Other Exchanges
N/A
Address
Section 4, Taiwan Avenue, 20th Floor-1, No. 925, Xitun District, Taichung, TWN
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.

We Can Medicines Co Headlines

No Headlines